TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...

A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.

Earlier MS diagnosis is now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise with summer ...

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...

Dr. Daniel Ontaneda, a neurologist with Cleveland Clinic, said more than two dozen approved medications can help control MS ...

New diagnostic criteria for multiple sclerosis are helping doctors identify the disease sooner, allowing patients to begin ...

Supplementation with high-dose vitamin D for more than one year significantly reduced relapse risk and eased disability in ...

Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, ...

The role of MRI in the assessment of multiple sclerosis (MS) goes far beyond the diagnostic process. MRI techniques can be used as regular monitoring to help stage patients with MS and measure disease ...

Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further ...

Multiple sclerosis, or MS, is a disease of the central nervous system that causes symptoms throughout the body. The progressive condition causes scar tissue, called lesions, along the nerve fibers in ...

Please provide your email address to receive an email when new articles are posted on . MSDA Test disease activity scores range from 1 (low) to 10 (high). Areas under the curve included 0.81 for Gd+ ...